Back to Search
Start Over
Reduction of direct and indirect costs in patients with AS receiving etanercept: results from an open-label 36-week extension of the ASCEND study in four European countries.
- Source :
-
Rheumatology . Feb2012, Vol. 51 Issue 2, p393-396. 4p. 1 Chart, 1 Graph. - Publication Year :
- 2012
-
Abstract
- Objective. To characterize the impact of etanercept (ETN) in AS on cost, work productivity and quality of life (QoL).Methods. A Phase 4, open-label, multi-centre (UK, Scandinavia) extension study in AS. Eligible subjects (n = 84) were treated for 36–52 weeks with ETN 50 mg s.c. once weekly. Analysis included direct costs (transformed out-patient and in-patient care elements), indirect costs (sick leave and lost working days), efficacy and QoL.Results. Annualized direct and indirect costs decreased (55.5%, P ≤ 0.008) during ETN treatment, as did out-patient and in-patient episodes (physiotherapist/physician visits, P = 0.012). Work productivity and QoL increased.Conclusion. ETN therapy significantly reduces direct and indirect health-care costs and increases work ability and QoL in AS.Trial Registration. EUDRACT, https://eudract.ema.europa.eu/, 2006-001061-42. [ABSTRACT FROM PUBLISHER]
Details
- Language :
- English
- ISSN :
- 14620324
- Volume :
- 51
- Issue :
- 2
- Database :
- Academic Search Index
- Journal :
- Rheumatology
- Publication Type :
- Academic Journal
- Accession number :
- 70947572
- Full Text :
- https://doi.org/10.1093/rheumatology/ker404